Extract from the Register of European Patents

EP About this file: EP0805153

EP0805153 - Novel muscarinic receptor agonists [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.09.2002
Database last updated on 11.04.2026
Most recent event   Tooltip17.04.2015Change - lapse in a contracting state
State(s) deleted from list of lapses: LU
published on 20.05.2015  [2015/21]
Applicant(s)For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
[N/P]
Former [1997/45]For all designated states
PFIZER INC.
235 East 42nd Street
New York, N.Y. 10017 / US
Inventor(s)01 / Liston, Dane R.
68 Main Street
Noank, Connecticut 06340 / US
02 / Nowakowski, Jolanta
10 Otter Brook Drive
Old Saybrook, Connecticut 06475 / US
03 / Villalobos, Anabella
47 Greencliff Drive
Niantic, Connecticut 06357 / US
04 / Yohannes, Daniel
25 Parkway South
New London, Connecticut 06320 / US
[1997/45]
Representative(s)Wood, David John, et al
Pfizer Limited European Patents Department, Ramsgate Road, Sandwich
Kent CT13 9NJ / GB
[N/P]
Former [1997/45]Wood, David John, et al
PFIZER LIMITED, European Patents Department, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date97302558.815.04.1997
[1997/45]
Priority number, dateUS1996001649430.04.1996         Original published format: US 16494
[1997/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP0805153
Date:05.11.1997
Language:EN
[1997/45]
Type: B1 Patent specification 
No.:EP0805153
Date:14.11.2001
Language:EN
[2001/46]
Search report(s)(Supplementary) European search report - dispatched on:EP28.08.1997
ClassificationIPC:C07D295/12, C07D295/18, C07D295/20, C07D213/74, A61K31/40
[1997/45]
CPC:
C07D213/75 (EP,US); A61P25/00 (EP); A61P25/04 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/24 (EP);
A61P25/26 (EP); A61P25/28 (EP); A61P43/00 (EP);
C07C257/20 (EP,US); C07D211/42 (EP,US); C07D211/44 (EP,US);
C07D211/46 (EP,US); C07D211/74 (EP,US); C07D265/02 (EP,US);
C07D277/04 (EP,US); C07D295/185 (EP,US); C07D295/195 (EP,US);
C07D295/215 (EP,US); C07D295/32 (EP,US); C07C2601/14 (EP,US);
C07C2603/74 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [1997/45]
TitleGerman:Muscarinische Rezeptor-Agonisten[1997/45]
English:Novel muscarinic receptor agonists[1997/45]
French:Agonistes du récepteur muscarinique[1997/45]
Examination procedure25.04.1997Examination requested  [1997/45]
07.06.1999Despatch of a communication from the examining division (Time limit: M04)
14.09.1999Reply to a communication from the examining division
27.09.1999Despatch of a communication from the examining division (Time limit: M06)
30.03.2000Reply to a communication from the examining division
21.12.2000Despatch of communication of intention to grant (Approval: Yes)
23.03.2001Communication of intention to grant the patent
19.06.2001Fee for grant paid
19.06.2001Fee for publishing/printing paid
Opposition(s)15.08.2002No opposition filed within time limit [2002/45]
Fees paidRenewal fee
10.04.1999Renewal fee patent year 03
10.03.2000Renewal fee patent year 04
04.04.2001Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipGR14.11.2001
[2015/21]
Former [2007/17]GR14.11.2001
LU30.04.2002
Former [2002/49]GR14.11.2001
Documents cited:Search[A] US5268373  (BRESLIN HENRY J et al.) [A] 1-17 * the whole document *
 [A] EP0034002  (BEECHAM GROUP PLC et al.) [A] 1-17 * the whole document *
 [A] US4269837  (WATT DAVID S et al.) [A] 1-17 * the whole document *
 [A] WO9200273  (BOOTS CO PLC et al.) [A] 1-17 * the whole document *
 [A] GB2226562  (BOOTS CO PLC et al.) [A] 1-17 * the whole document *
 [A] WO9400448  (BOEHRINGER INGELHEIM ITALIA et al.) [A] 17-22 * page 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.